Suppr超能文献

[可溶性髓系细胞触发受体-1在脓毒症诊断中的研究进展]

[Research progress of presepsin in sepsis diagnosis].

作者信息

Yu Hui, Zeng Yuanlin, Zhou Congyang

机构信息

Department of Emergency, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China (Yu H, Zhou CY, Zeng YL); Postgraduate School, Nanchang University Medical College, Nanchang 330006, Jiangxi, China (Yu H). Corresponding author: Zhou Congyang, Email:

出版信息

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Aug;29(8):756-759. doi: 10.3760/cma.j.issn.2095-4352.2017.08.018.

Abstract

Sepsis is a frequently met syndrome with complex clinical symptoms and high mortality in emergency department. Early diagnosis of sepsis and timely treatment can improve survival. In recent years, the application of biomarkers [such as procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6)] are commonly used in the early diagnosis of sepsis, but their specificity and sensitivity are limited because of the long lag of report time. Soluble leukocyte differentiation antigen 14 sub type (sCD14-ST, namely presepsin) is a kind of novel biomarkers. Presepsin has a high specificity and sensitivity in the diagnosis of sepsis. It has some value to evaluate the severity of sepsis, antibiotic treatment of antibiotics, and prognosis of the patients with sepsis, and its latest detection method is fast and accurate, so it has the feasibility of clinical application.

摘要

脓毒症是急诊科常见的综合征,临床症状复杂,死亡率高。早期诊断脓毒症并及时治疗可提高生存率。近年来,生物标志物[如降钙素原(PCT)、C反应蛋白(CRP)、白细胞介素-6(IL-6)]常用于脓毒症的早期诊断,但由于报告时间滞后较长,其特异性和敏感性有限。可溶性白细胞分化抗原14亚型(sCD14-ST,即可溶性髓系细胞触发受体-1)是一种新型生物标志物。可溶性髓系细胞触发受体-1在脓毒症诊断中具有较高的特异性和敏感性。它在评估脓毒症的严重程度、抗生素治疗及脓毒症患者的预后方面具有一定价值,且其最新检测方法快速准确,具有临床应用的可行性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验